Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vandetanib + etoposide
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Vandetanib + etoposide is a combination of two antineoplastic agents used in oncology, though not as a fixed-dose combination product. Vandetanib is an oral small molecule tyrosine kinase inhibitor that targets multiple receptors involved in tumor growth and angiogenesis, including the epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptors (VEGFR), and RET proto-oncogene. It is primarily approved for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease[1][3]. Etoposide is a semisynthetic derivative of podophyllotoxin that acts as a topoisomerase II inhibitor, leading to DNA strand breaks and inhibition of cell division. It is mainly used to treat testicular cancer and small cell lung cancer but has applications in other malignancies[2][5][6]. Both drugs are administered as part of multi-agent chemotherapy regimens for various cancers.
- Brand names
- Zactima
- Other names
- ToposarVP-16VP16VP 16
02
Targets
EGFR (Epidermal growth factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)TOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on vandetanib + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vandetanib + etoposide.